$THC

HANEY CECIL D sold $361K of THC

HANEY CECIL D sold 1,300 shares of TENET HEALTHCARE CORP (THC) at $278.03 ($0.36M total) on 2026-08-24.

Original reporting
SEC EDGAR · HANEY CECIL D
Published Aug 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 12:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Bearish
medium confidence
Mentioned
$THC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCBearishLow
01

Why it matters

A director's sale of 1,300 shares for $361k is disclosed for the first time, providing new data for traders monitoring insider activity.

02

Market read

First‑report insider sale; modest size but may influence short‑term sentiment.

03

What to watch

No accompanying corporate news; the director retains a sizable stake.

Relevance 4/10Novelty 4/10Timing: post‑market filing on Aug 26

Background

SEC Form 4 filing discloses insider transactions. Tenet Healthcare (THC) is a NYSE‑listed healthcare services company.

Company-level read

Ticker impact

$THCBearishMedium confidence
Context

Director Haney Cecil D sold 1,300 shares of Tenet Healthcare for $361,439.

Expected impact

Modest short-term downside pressure

Evidence & confidence

Director sales are closely watched; a $361k sale is modest but could trigger sell‑offs among short‑term traders.

Market effects

Minimal impact on healthcare sector; typical insider transaction.

None

Low

Counterpoint

The sale may be routine portfolio rebalancing, not a negative signal.

Key entities

  • Tenet Healthcare Corp

    NYSE‑listed healthcare services provider.

  • Haney Cecil D

    Director of Tenet Healthcare who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

$THCMedAI 8/10

Tenet Healthcare at Wells Fargo conference: high-acuity push deepens

Tenet Healthcare (THC) presented at the Wells Fargo Healthcare Conference, outlining a strategy focused on high-acuity care, capital spending, and cost control. The company raised full-year guidance, citing volume growth and cost discipline. Shares are near their 52-week high at $268.82, up over 30% year-to-date. Tenet expects continued pressure in some payer channels and near-term earnings drag from Conifer's transition. Management plans to invest in complex procedures and maintain capital spen